Uncovering a Potential Biomarker for Myasthenia Gravis
Developments in DMD Treatment: The First Nonsteroidal Drug Approval
The CLL Landscape: A Look at Current and Future Therapies
Navigating CLL Treatment: A Deep Dive into Efficacy and Safety
Peter E. Newburger, MD
PeerJacob R. Bledsoe, MD
PeerPeter E. Newburger, MD
PeerJolan Walter, MD, PHD
PeerPeter E. Newburger, MD
PeerIgAN Insights: The Potential Role of the Complement System in Disease Progression
Jean Francis, MD
PeerIdentifying Patients at High-Risk for IgAN Progression: Key Factors to Know
Exploring Early Usage of a 2L ITP Treatment Option: Clinical Profile and Access Resources
Managing Refractory Cytomegalovirus Post-Solid Organ Transplant
Investigating HLH: Our Current Understanding of a Rare Disease
Managing Refractory Cytomegalovirus After Hematopoietic Cell Transplant